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Abstract
To characterize the radiation-enhancing effects on human
cancer cells and underlying mechanisms of celecoxib, a
cyclooxygenase (COX)-2 selective inhibitor, and to ascertain
whether its effects are COX-2 dependent. Clonogenic cytotox-
icity assays and radiation survival assays after treatment
with celecoxib F radiation were done on four human cancer
cell lines that expressed differential COX-2 levels. Stably COX-2
knocked down or overexpressed cell lines were developed,
and clonogenic assays, apoptosis assays, or cell cycle change
measurements were conducted after treatment with cele-
coxib F radiation. Prostaglandin E2 (PGE2) was applied to
medium after treatment with celecoxib F radiation to
determine whether the radiation-enhancing effect associated
with celecoxib results from reduced generation of prosta-
glandin. Celecoxib’s radiation-enhancing effect was observed
in COX-2–expressing A549 and NCI-H460 cells but was not
observed in the COX-2 nonexpressing MCF-7 and HCT-116
cells. Celecoxib’s radiation-enhancing effects in A549 cells
were shown to disappear after the administration of COX-2
knocked down. In contrast, the HCT-116 cells were radio-
sensitized by celecoxib after being transfected with COX-2
expression vector. The addition of PGE2 after treatment with
celecoxib F radiation had no significant effects on celecoxib’s
radiation-enhancing effects in A549 and COX-2 transfected
HCT-116 cells. Radiation-induced G2-M arrest was enhanced
and sustained in the COX-2–overexpressing cells compared
with that seen in COX-2 low-expressing cells. Celecoxib or
NS-398 effected no changes or attenuated radiation-induced
G2-M arrest in the COX-2–overexpressing cells but further
enhanced the radiation-induced G2-M arrest in the COX-2
low-expressing cells. Celecoxib’s radiation-enhancing effects
seem to occur in a COX-2 expression-dependent manner in
the cancer cells. This effect does not seem to be the result of
reduced PGE2 generation. Celecoxib may exert an inhibitory
effect on enhanced radiation-induced G2-M arrest in the
COX-2–overexpressing cells, which may allow the arrested
cells to enter mitosis and die after radiation, but may also
further enhance radiation-induced G2-M arrest in the COX-2
low-expressing cells, by virtue of another mechanism. (Cancer
Res 2005; 65(20): 9501-9)
Introduction
Cyclooxygenase (COX) is a key enzyme that catalyzes the
conversion of arachidonic acid to prostaglandins as well as other
prostanoids. Two COX isoforms have, thus far, been identified.
COX-1 is constitutively expressed in a variety of cell types and
seems to be intimately involved in the homeostasis of several
physiologic functions, whereas COX-2 is an inducible enzyme,
which is regulated by various factors, including cytokines, growth
factors, and tumor promoters (1, 2).
Increased COX-2 expression has been observed to occur in a host
of tumor types in both humans and animals, and COX-2 selective
inhibitors have been reported to prevent carcinogenesis and have
also been shown to ameliorate the growth rate of tumor cells both
in vitro and in vivo . In addition, COX-2 selective inhibitors are
known to sensitize the tumor cells to both chemotherapeutic
agents and ionizing radiation (3).
A myriad of studies have been conducted to elucidate the
mechanism underlying the antitumor effects associated with COX-2
inhibitors. However, this mechanism has yet to be clearly defined. In
addition, debates have raged continuously for a long period over
whether the effects of COX-2 selective inhibitors occur in a COX-2
expression-dependent manner in the cancer cells. Several research-
ers have also reported recently that COX-2 selective inhibitors exert
both COX-2–dependent and COX-2–independent antineoplastic
effects (4–11).
In terms of the COX-2 dependency of the COX-2 selective
inhibitor with regard to radiosensitization, we showed in a
previous study that NS-398, a COX-2 selective inhibitor, augmented
the effects of radiation in COX-2-overexpressing cells, but this was
not found to be true in COX-2 nonexpressing cells (12).
To further clarify this issue, we assessed celecoxib, another COX-2
inhibitor that is currently clinically employed in the treatment of
patients with arthritis, on four human cancer cell lines, each of
which expressed different COX-2 protein levels. We also constructed
and tested COX-2 knocked down cells from A549 cells constitutively
expressing high COX-2 levels as well as COX-2-overexpressing cells,
which were derived from HCT-116 cells expressing essentially no
COX-2, to confirm or disconfirm the COX-2 dependency of the
radiation-enhancing effects of the COX-2 selective inhibitor,
celecoxib.
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Materials and Methods
Reagents. Celecoxib was kindly provided by Pharmacia Corp. (Skokie, IL).
Cell culture. A549 human lung adenocarcinoma, MCF-7 human breast
carcinoma, NCI-H460 human lung large cell carcinoma, and HCT-116
human colon adenocarcinoma cells were all acquired from the American
Type Culture Collection (Manassas, VA) and were cultured in the recom-
mended medium supplemented with 10% fetal bovine serum (Life
Technologies, Gaithersburg, MD), 50 units/mL penicillin (Life Technologies),
and 50 Ag/mL streptomycin (Life Technologies). Cells were carried for no
more than eight passages, and only cultures that were <90% confluent were
used in all of the experiments.
Reverse transcription-PCR. Total cellular RNA was extracted with
TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instruction. Total RNA (2 Ag) was reverse transcribed for 1 hour at 37jC
in a reaction mixture that contained 5 units RNase (Amersham Pharmacia
Biotech, Piscataway, NJ), 0.5 mmol/L deoxynucleotide triphosphate
(Boehringer Mannheim, Indianapolis, IN), 2 Amol/L random hexamer
(Stratagene, La Jolla, CA), 1 reverse transcriptase buffer, and 5 units
reverse transcriptase (Qiagen, Valencia, CA). We conducted PCR using
primers for COX-2 (5V-ATACTAGAGCCCTTCCTCCTGT-3V and 3V-GCA-
TACTCTGTTGTGTTCCCTC-5V) and glyceraldehyde-3-phosphate dehydro-
genase, which was used as an invariant housekeeping gene internal control
(5V-CAGGGCTGCTTTTAACTCTG-3V and 3V-GTCATGAGTCCTTCCACGA-
TAC-5V). Analysis of the resultant PCR products on 1% agarose gel revealed
single-band amplification products of the expected sizes.
Immunoblotting. The cells were lysed for 30 minutes at 4jC in
radioimmunoprecipitation assay buffer (1 PBS, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 1 mmol/L EDTA) containing 10 Ag/mL aprotinin,
10 Ag/mL leupeptin, 1 Ag/mL pepstatin, and 100 Ag/mL phenylmethylsul-
fonyl fluoride. The protein concentration of the supernatant in the
centrifuged cell lysates was determined using a Bio-Rad Protein Assay kit
(Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s
instructions. Proteins (50 Ag) were then denatured and fractionated on
polyacrylamide gels, which contained SDS, and then transferred to
polyvinylidene difluoride membranes after electrophoresis. The filters were
then incubated overnight at 4jC in blocking solution (PBS containing 5%
nonfat, dried milk and 0.1% Tween 20) followed by 1-hour incubation with
anti-COX-2 antibodies. Rabbit polyclonal anti-human COX-2 antibody
(Cayman Chemical, Ann Arbor, MI) was used at a dilution of 1:1,000. The
filters were washed five times and incubated with a horseradish
peroxidase–conjugated anti-rabbit immunoglobulin as a secondary anti-
body for 1 hour at a 1:5,000 dilution. After five additional washes, the filters
were developed with an enhanced chemiluminescence system (Amersham
Pharmacia Biotech) and exposed to Hyperfilm enhanced chemilumines-
cence. The membranes were also probed with anti-actin antibody (Sigma,
St. Louis, MO) to normalize the differences between the samples.
Quantitation was conducted via video densitometry.
Clonogenic assay for cytotoxicity measurement and radiation
survival experiment. Log-phase cells in 75-cm2 cell culture flasks were
trypsinized and then quantified with a hemocytometer. The cells were then
serially diluted to the appropriate concentrations and plated out in
triplicate per data point into 25-cm2 cell culture flasks. The cells were then
permitted to attach for 24 hours at 37jC. Stock celecoxib solutions were
constructed via the dissolution of the compound in DMSO (Sigma) and then
stored at 20jC. Immediately before the commencement of the experi-
ments, we diluted the stock solutions in DMSO to the appropriate
concentrations. To measure cytotoxicity, the cells were exposed to a vehicle
(DMSO) or to various celecoxib concentrations for 72 hours. The cells were
then rinsed with PBS and allowed to grow in drug-free medium. In the
radiation survival experiment, the cells were exposed to a vehicle (DMSO) or
to various celecoxib concentrations for 4 hours. The cells were then
irradiated with graded doses of g-rays using the Gammacell 3000 Elan
system (MDS Nordion, Inc., Ontario, Canada), at a dose rate of 10.7 Gy/min,
as determined by thermoluminescence dosimetry for the specific system
employed. After an additional 68 hours of incubation in medium containing
either the vehicle or the drug, the cells were rinsed with PBS, and drug-free
medium was added. The final DMSO concentration was adjusted to 0.2% in
all flasks. The cells were then maintained at 37jC for 6 to 8 days to allow for
the formation of colonies and then stained with 0.5% crystal violet (Sigma)
in absolute methanol. The colonies were counted visually with a cutoff value
of 50 viable cells. The surviving fraction was then calculated as follows:
mean number of colonies / (number of cells inoculated  plating
efficiency), where plating efficiency is defined as the mean number of
colonies / number of cells inoculated for untreated controls. Surviving
fractions in the cells exposed to radiation plus celecoxib were normalized by
dividing by the surviving fraction obtained for celecoxib alone. We then
calculated the dose enhancement ratio (DER) as the dose (Gy) for the
radiation plus vehicle cells divided by the dose (Gy) for radiation plus
celecoxib (normalized for drug toxicity) at a surviving fraction of 0.1. Error
bars were also calculated as SE via the pooling of the results of three
independent experiments.
Development of stably COX-2 knocked down cells by RNA
interference. We designed and synthesized complementary oligonucleo-
tides against human COX-2, containing 5V single-strand overhangs for
ligation into the pSilenCircle (Allele Biotechnology, San Diego, CA) vector
for three small interfering RNA (siRNA) target candidate sequences. One
candidate target sequence (5V-acaccGAACGTTCGACTGAACTGTttgcttgaa-
ACAGTTCAGTCGAACGTTCt-3V and 3V-aaaaaGAACGTTCGACTGAACTGT-
ttcaagcaaACAGTTCAGTCGAACGTTCg-5V) was shown to work properly by
the results of a gene knockdown assay, which employed reverse
transcription-PCR (RT-PCR) and Western blotting. The negative control
sequence was adopted from the general negative sequence (Ambion, Inc.,
Austin, TX). The oligonucleotides were then annealed and ligated into the
pSilenCircle vector. Transfection was conducted with LipofectAMINE
reagent (Invitrogen) in accordance with the manufacturer’s instructions.
Positive transfectants were selected in medium, which contained 500 units/
mL G418 (Life Technologies). All cell lines were derived from individual
colonies via cloning cylinders.
Development of stably transfected cells with COX-2 cDNA. The
human COX-2 expression vector (pSG5-COX-2 plasmid, kindly provided by
Dr. S.J. Lim, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea),
which harbors a full-length COX-2 cDNA, was transfected into HCT-116 cells
that have been grown in six-well tissue culture plates at a density of 3  105
cells per 2 mL medium. The transfection and selection of the positive
transfectant were conducted as described above using 200 Ag/mL
hygromycin (Life Technologies).
Detection of cell cycle changes and apoptosis via flow cytometry. In
brief, 2.5  105 to 5  105 cells were plated into 25-cm2 flasks for the
determination of each data point. After 24 hours, the cells were exposed to
the appropriate concentrations of celecoxib or vehicle (DMSO) for 4 hours
and then exposed to graded doses of g-rays. After an additional 20, 44, or 68
hours of incubation in medium, which contained either the drug or the
vehicle, the cells were trypsinized (retaining all floating cells), fixed with 75%
ethanol at 20jC overnight, and then incubated at room temperature for 3
hours with 10 Ag/mL propidium iodide (Sigma) and 5 Ag/mL RNase A
(Amresco, Solon, OH). The number of cells at each cell cycle as well as the
cells that have undergone apoptosis (sub-G1) was evaluated with the
FACSCalibur system (Becton Dickinson, San Jose, CA). Error bars were also
calculated as SE by the pooling of the results of three independent
experiments. The same samples were then mounted on slide glasses and
were reanalyzed under fluorescent microscopy.
Statistical analysis. Data were expressed as means F SE and then
analyzed with regard to statistical significance using ANOVA followed by
Scheffe’s test for multiple comparisons. P < 0.05 was considered to be
significant.
Results
Cytotoxicity of celecoxib on cancer cells. A549 cells exhibited
a high constitutive COX-2 protein expression level, and the NCI-
H460 cells expressed relatively low COX-2 levels. The MCF-7 and
HCT-116 cells manifested no detectable expression of the COX-2
protein (Fig. 1). To assess celecoxib’s cytotoxicity on cancer cells,
Cancer Research
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the cells were exposed to various celecoxib dosages for 72 hours
and then permitted to form colonies in drug-free medium.
Clonogenic cytotoxicity values for celecoxib in the different cancer
cells were not found to differ significantly according to COX-2
expression levels in these cells (data not shown).
Celecoxib’s effects on the radiosensitivity of various cancer
cells. To assess and characterize the radiation-enhancing effects of
celecoxib, the cells were exposed to graded doses of g-radiation
either with or without IC50 concentrations of celecoxib treatments
for 72 hours. These cells were all then permitted to form colonies in
drug-free medium. Radiation was administered 4 hours after the
start of drug treatment. Celecoxib was determined to augment the
effects of radiation in the A549 and NCI-H460 cells, and the DER
values were determined to be 1.6 to 1.9 and 1.2 at a surviving fraction
of 0.1, respectively (Fig. 2A and C). However, celecoxib exerted no
radiation-enhancing effects in the MCF-7 and HCT-116 cells (Fig. 2B
andD). Various celecoxib concentrations (20-60 Amol/L) were tested
in the MCF-7 and HCT-116 cells, but we were unable to detect any
enhancement of radiation effects (data not shown).
Celecoxib’s effects on the clonogenic survival of A549-mock
and A549-COX-2 knockdown cells. To determine whether
celecoxib’s radiation-enhancing effects in A549 cells occur in a
COX-2-dependent manner, a stably COX-2 knocked down cell
line (AS), which employed the siRNA expression vector for COX-2,
and its mock control cell line (AN), were developed from A549
cells, and we conducted a series of clonogenic assays with these
cells. The AS line exhibited >90% knockdown of COX-2 mRNA
and protein expression compared with its parent cells, whereas
we witnessed no changes in COX-2 expression in the AN cells
(Fig. 3A). Prostaglandin E2 (PGE2) generation in the AN cells was
comparable with that observed in the A549 parent cells. However,
PGE2 generation in the AS cells was noted to have decreased to
1% that observed in the parent or the AN cells (Table 1).
Figure 1. Western blot analysis for COX-2 expression in A549, MCF-7,
NCI-H460, and HCT-116 cells. +Ve, positive control of COX-2 (ovine COX-2
electrophoresis standard). A549 cells showed high level of constitutive COX-2
protein expression, NCI-H460 cells expressed low level of COX-2, and MCF-7
and HCT-116 cells exhibited no constitutive COX-2 expression.
Figure 2. Clonogenic survival curves for radiation +
celecoxib in A549 (A), MCF-7 (B), NCI-H460 (C ), and
HCT-116 (D) cells. Cells attached to the flasks were
treated with celecoxib for 4 hours, irradiated, rinsed after
another 68 hours, and allowed to form colonies in drug-free
medium. Surviving fractions for radiation + celecoxib
were normalized by dividing by the surviving fraction for
celecoxib only. A, ., radiation + vehicle (DMSO) treatment;y, radiation + 30 Amol/L celecoxib; n, radiation + 50 Amol/L
celecoxib in A549 cells. B, ., radiation + vehicle (DMSO)
treatment; n, radiation + 40 Amol/L celecoxib in MCF-7
cells. C, ., radiation + vehicle (DMSO) treatment; E,
radiation + 50 Amol/L celecoxib in NCI-H460 cells. D, .,
radiation + vehicle (DMSO) treatment; n, radiation +
40 Amol/L celecoxib in HCT-116 cells. Bars, SE
of three independent experiments in triplicate.
COX-2-overexpressing A549 cells exhibited
dose-dependent radiation-enhancing effects as the
result of celecoxib treatment (A ), and COX-2-expressing
NCI-H460 cells exhibited lesser degrees of
radiation-enhancing effects than did the A549 cells (C ).
By way of contrast, COX-2 nonexpressing MCF-7 (B )
and HCT-116 (D ) cells exhibited no radiation-enhancing
effects as the result of treatment with this drug.
Radiosensitivity Enhancement by Celecoxib
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Celecoxib-associated cytotoxicity was similar in both cell lines
(Fig. 3B). Celecoxib-associated radiation-enhancing effects were
observed in the AN cells, but these effects disappeared in the AS
cells (Fig. 3C and D).
Celecoxib’s effects on the clonogenic survival of HCT-116-
mock and HCT-116-COX-2 overexpressed cells. To determine
whether the lack of celecoxib’s radiation-enhancing effects in the
HCT-116 cells could be reversed via the induction of COX-2
expression in these cells, we constructed both a stably COX-2
transfected HCT-116 cell line (HCT-116-COX-2) and a mock control
cell line (HCT-116-mock). We then conducted a series of clonogenic
assays on both of these cell lines. The HCT-116-COX-2 cells were
observed to express significant quantities of the COX-2 protein,
comparable with that seen in the A549 cells, and this was a
functional protein, whereas the HCT-116-mock cell line was shown
to express no COX-2 (Fig. 4A ; Table 1). The HCT-116-COX-2 cells
were more sensitive to celecoxib treatment than were the HCT-116-
mock cells (Fig. 4B). The HCT-116-mock cell line manifested no
detectable radiation-enhancing effects as the result of celecoxib
exposure. However, HCT-116-COX-2 cells evidenced a mild radia-
tion-enhancing effect on exposure to this drug (Fig. 4C and D).
Effects of prostaglandin E2 addition after radiation treat-
ment combined with celecoxib in the A549 and HCT-116-COX-
2 cells. To determine whether the radiation-enhancing effects of
celecoxib in the A549 and HCT-116-COX-2 cells were attributable
to the reduced prostaglandin generation as the result of treatment
with this drug, PGE2, a primary product of the COX-2 enzyme, was
added to the cells after the administration of celecoxib and/or
radiation treatment, after which we conducted a set of clonogenic
radiation survival experiments. After testing a variety of PGE2
concentrations (10 nmol/L-10 Amol/L) for the clonogenicity of
A549 and HCT-116-COX-2 cells, 500 nmol/L PGE2 (equals 176.3 ng/
mL), which is equivalent to the maximum inducible concentration
in the A549 cells (refs. 13–18; Table 1), was added to the medium to
supply a sufficient amount of PGE2 but not to exceed the
physiologic range. This PGE2 concentration was not found to
affect the clonogenic survival of the A549 and HCT-116-COX-2 cells
when administered alone. PGE2 administration was also shown not
to affect the clonogenic radiation survival characteristics of these
cells, nor did it detectably affect the radiation-enhancing effects
associated with celecoxib treatment (data not shown).
Effects of celecoxib on apoptotic induction in AN, AS, HCT-
116-mock, and HCT-116-COX-2 cells. We then attempted to
determine whether the radiation-enhancing effects of celecoxib in
the AN and HCT-116-COX-2 cells but not in the AS and HCT-116-
mock cells was attributable to differences in apoptotic induction by
this drug in these cells. In brief, the cells were exposed to celecoxib
for up to 72 hours, either with or without radiation, and the
fraction of sub-G1 was then calculated to measure the rate of
apoptosis after flow cytometric analysis. The apoptosis induction
rates associated with treatment with 50 or 40 Amol/L celecoxib
alone ( for AN and AS or HCT-116-COX-2 and mock, respectively)
were relatively low in all of the tested cell lines. Apoptotic
induction rates after radiation and celecoxib treatment did not
Figure 3. Clonogenic cytotoxicity and radiation
survival curves for radiation F celecoxib in the
stably COX-2 knocked down cells developed
from A549 cells via transfection with COX-2
siRNA-expressing vector. A, results of RT-PCR
(top ) and Western blots (bottom ) for COX-2
expression. P, A549 parent cells; AN, COX-2
knocked down A549 cells; AS, mock control
A549 cells transfected with a general negative
sequence harboring vectors. B, clonogenic
cytotoxicity curves for celecoxib in AN and AS
cells. o, AN; n, AS. C, clonogenic survival
curves for radiation + celecoxib in AN. o,
radiation + vehicle (DMSO) treatment; 5,
radiation + 50 Amol/L celecoxib. D, clonogenic
survival curves for radiation + celecoxib in AS.
o, radiation + vehicle (DMSO) treatment; 4,
radiation + 50 Amol/L celecoxib. Bars, SE of
three independent experiments in triplicate. AN
exhibited almost identical COX-2 expression
with that of the A549 parent cells, and AS
manifested >90% reduction of COX-2 mRNA
and protein expression (A). We detected no
differences in clonogenic cytotoxicity between
these two cell lines (B). Celecoxib sensitized AN
cells to radiation, but this effect disappeared in
the AS cells (C and D ).
Cancer Research
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seem to have undergone a synergistic increase in any of the cells
when compared with the values observed after the administration
of each treatment separately (Table 2).
Celecoxib’s effects on cell cycle regulation in the AN, AS,
HCT-116-mock, and HCT-116-COX-2 cells. To determine whether
the radiation-enhancing effects of celecoxib in the AN and HCT-116-
COX-2 cells but not in the AS and HCT-116-mock cells was related to
cell cycle regulation as a result of treatment with this drug, the
number of cells in each cell cycle phase was determined via flow
cytometric analyses after the administration of celecoxib treatment,
either with or without radiation in these cell lines, for up to 72 hours.
All four of the tested cell lines exhibited significantly increased rates
of G0-G1–phase cells after the administration of 50 or 40 Amol/L
celecoxib ( for AN and AS or HCT-116-COX-2 and mock cells,
respectively), and we determined there to be no differences resulting
from differential COX-2 expression levels in these cells (data not
shown). AN and HCT-116-COX-2 manifested significantly higher and
sustained rates of G2-M–phase cells compared with what was
observed with the AS and HCT-116-mock cells, respectively, when
treated with 9 Gy (AN and AS) or 6 Gy (HCT-116-mock and HCT-116-
COX-2) of radiation alone (Fig. 5). Celecoxib treatment combined
with radiation in the AS and HCT-116-mock cells resulted in
significantly increased and sustained rates of G2-M–phase cells
compared with what was observed as the result of radiation
administered alone in each cell lines, whereas combined treatment
in the AN cells resulted in only minor differences in the rate of G2-M
cells compared with what was seen with radiation alone. Combined
treatment in the HCT-116-COX-2 cells resulted in a reduction in the
amount of G2-M–phase cells comparedwith whatwas observedwith
radiation alone (Fig. 5A and B). We also tested another COX-2
selective inhibitor, NS-398, to ascertain whether the effects on cell
cycle changes observed in conjunction with celecoxib treatment
were similar to the effects reported in association with other COX-2
selective inhibitors. Combined treatment with NS-398 (at a IC50
concentration for clonogenic death after 72 hours of drug treatment)
and radiation in HCT-116-mock cells was reported to both increase
and sustain the rate at which cells were found in the G2-M phase
compared with what was observed after the administration of
radiation only. However, we noted only minor changes in HCT-116-
COX-2 cells (Fig. 5C). This is consistent with the results obtained
using celecoxib, although the reduction in the amount of cells found
in the G2-M phase was not observed in this experimental setting
after the treatment of our experimental cells with a combination of
the drug and radiation.
Discussion
Although many results have been reported with regard to the
radiosensitizing effects exerted by COX-2 selective inhibitors on a
variety of cancer cells (12, 19–26), the mechanisms underlying these
effects have yet to be clearly understood. There is also little
available data, at this point, regarding COX-2-dependent radio-
sensitization by COX-2 selective inhibitors. In our previous study,
we determined that NS-398 could enhance the radiosensitivity of
only COX-2-overexpressing RIE-S and NCI-H460 cells (12). In the
current study, we evaluated four human cancer cell lines with a
variety of pathologic cell types culled from several different organs
and determined that celecoxib, another clinically available COX-2
selective inhibitor, also enhanced the effect of radiation only in
COX-2-overexpressing A549 and NCI-H460 cells and did not
enhance the effect of radiation in COX-2 nonexpressing MCF-7
and HCT-116 cells. However, the cytotoxicities of celecoxib alone
were not shown to be dependent on COX-2 expression levels. This
result is consistent with the results from the previous study.
Moreover, we studied celecoxib-associated radiosensitization in
COX-2 knocked down A549 and COX-2 overexpressed HCT-116
cells to confirm the COX-2 dependency inherent to the radio-
sensitization effects of this drug. We discovered that the previously
described radiation-enhancing effects of celecoxib disappeared
when the COX-2 was knocked down in the A549 cells by RNA
interference, whereas the lack of radiosensitization as the result of
celecoxib treatment in the COX-2-negative HCT-116 cells was
reversed after the transfection of COX-2 cDNA in these cells.
According to the results of our previous and current studies, it can
be inferred that COX-2 selective inhibitors primarily affect the
sensitization of COX-2–expressing cells to radiation and do not
tend to confer this sensitivity to COX-2 nonexpressing cells. This
may, in fact, constitute a common feature of COX-2 inhibitors.
Therefore, it would be reasonable to surmise that radiosensitiza-
tion as the result of treatment with COX-2 selective inhibitors
occurs via a COX-2 protein-dependent mechanism in the cells.
A549 cells, which express high COX-2 levels, exhibited higher DER
values as the result of celecoxib treatment than were observed in
NCI-H460 cells, which express relatively low COX-2 levels. However,
the DER values seen as the result of celecoxib treatment in the HCT-
116-COX-2 cells were lower than that in the A549 cells despite the
comparable COX-2 expression levels in these two cell lines. This
suggests that the COX-2–dependent radiation-enhancing effects
associated with celecoxib are dependent on the presence of COX-2
protein in the cells but are not dependent on the levels of COX-2
expression, and the DER values of the COX-2 selective inhibitors
may be determined principally by other factors in the cells.
We reported in a previous study that the mechanism underlying
the radiation-enhancing effects of NS-398 in RIE-S and NCI-H460
cells may be attributable to the enhancement of radiation-induced
apoptosis as the result of treatment with this drug (12). However,
only a minor amount of apoptotic induction was noted as the
Table 1. PGE2 production in AN, AS, HCT-116-mock, and
HCT-116-COX-2 cells before and after stimulation by
adding arachidonic acid into medium for 24 hours
Cells PGE2 concentration
(ng/million cells)
SE*
Unstimulated
A549 parent 5.2 0.4
AN 5.0 0.5
AS 0.06 0.01
HCT-116-parent 0.004 0.0008
HCT-116-mock 0.006 0.0009
HCT-116-COX-2 10.3 0.9
Stimulated by 10 Amol/L arachidonic acid
A549 parent 8.4 0.5
AN 7.5 2.4
AS 0.4 0.08
HCT-116-parent 0.5 0.01
HCT-116-mock 0.2 0.02
HCT-116-COX-2 52.5 2.3
*SE from two independent experiments.
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result of celecoxib treatment, with or without radiation, in the AN,
AS, HCT-116-mock, and HCT-116-COX-2 cells evaluated in the
current study. In addition, the degree to which apoptosis was
induced by celecoxib and radiation was not determined to be
synergistically increased in the COX-2-overexpressing AN and HCT-
116-COX-2 cells. The reasons for this difference between the results
of the previous and current study will require further study before
they can clearly elucidated, but different drug incubation times
(24 hours for NS-398 versus 72 hours for celecoxib) may be partially
responsible for radiosensitization occurring as the result of
different mechanisms; treatment with a high concentration of
COX-2 selective inhibitors for a short time may affect the
sensitization of the cells via a pathway involving apoptosis. By
way of contrast, treatment with low concentrations of COX-2
selective inhibitors for a prolonged period may exert an effect via
completely different mechanisms, such as cell cycle modulation.
These will be discussed later in this section.
After we had confirmed the COX-2-dependent radiosensitization
by COX-2 selective inhibitors occurring in the current study, we
became curious as to whether the radiosensitizing effects observed
in the COX-2 expressing cells was perhaps attributable to an
attenuation of prostaglandin generation as the result of treatment
with these drugs. Reports regarding prostaglandin treatment for the
modulation of cancer cell radiosensitivity have not been consistent.
PGE1, PGE2, and their analogues have been shown to protect normal
tissues from radiation but not cancer cells (27, 28). Some
prostaglandins have been shown, in fact, to potentiate radiation
toxicity in cancer cells (29, 30). To characterize the relationship
between attenuated prostaglandin generation and radiation sensi-
tivity or radiosensitization of cells as the result of COX-2 selective
inhibitors, we treated cells with PGE2, a primary product of COX-2
in the tested cells (31), at a concentration that was believed to be
sufficiently high for the verifiable emergence of its effects but within
a physiologic range that would preclude its own cytotoxic effects or
unexpected nonphysiologic effects in the cells. The addition of PGE2
was determined neither to alter radiation survival rates nor to
reverse celecoxib’s radiation-enhancing effects on A549 and HCT-
116-COX-2 cells. This result suggests that physiologic PGE2
concentrations have no effect on radiation survival rates of cancer
cells and also that celecoxib-induced radiosensitization may not
constitute the result of attenuated prostaglandin generation.
Therefore, signals for radiation-enhancing effects resultant from
treatment with COX-2 selective inhibitors may be mediated by the
COX-2 protein itself or by substrates or enzymes in the upstream
regions of this protein but not by its end product.
COX-2 selective inhibitors are well known to modulate the cell
cycles of both normal and cancer cells. COX-2 selective inhibitors
have been shown to primarily induce G0-G1 arrest (4, 9, 32–36);
however, some drugs have been shown, under some conditions, to
induce G2-M arrest (22, 37, 38). Several researchers did cell cycle
analyses to investigate the mechanisms underlying the radiation-
enhancing effects of the COX-2 selective inhibitors. However, most of
this research involved the measurements of cell cycle changes after
treatment with COX-2 selective inhibitor in the absence of radiation,
Figure 4. Clonogenic cytotoxicity and radiation survival
curves for radiation F celecoxib in the stably COX-2
overexpressed cells developed from the HCT-116 cells
via the transfection of COX-2 expression vector. A,
Western blots for COX-2 expression. +Ve, positive COX-2
control. B, clonogenic cytotoxicity curves for celecoxib in
the HCT-116-mock (o) and HCT-116-COX-2 (n) cells.
C, clonogenic survival curves for radiation + celecoxib in
HCT-116-mock cells. o, radiation + vehicle (DMSO)
treatment; n, radiation + 40 Amol/L celecoxib. D,
clonogenic survival curves for radiation + celecoxib in
HCT-116-COX-2 cells. o, radiation + vehicle (DMSO)
treatment; n, radiation + 40 Amol/L celecoxib. Bars, SE
of three independent experiments in triplicate.
HCT-116-mock cells exhibited no COX-2 expression,
whereas the HCT-116-COX-2 cells expressed an amount
of COX-2 comparable with that of A549 cells (A).
HCT-116-COX-2 cells were determined to be more
sensitive to celecoxib than were the HCT-116-mock cells
(B ). HCT-116-mock cells exhibited no radiation-enhancing
effects, whereas HCT-116-COX-2 cells exhibited a mild
radiation-enhancing effect as the result of celecoxib
treatment (C and D ).
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or involved only one cell line, without regard to the COX-2 expression
inherent to that line (21, 22, 38). Therefore, there have been no
previous comparative analyses conducted regarding cell cycle
modulation after combined treatment of COX-2 selective inhibitors
with radiation according to differences in COX-2 expression in the
cells. In the current study, we measured changes in the amount of
cells in each cell cycle phase in AN, AS, HCT-116-mock, andHCT-116-
COX-2 cells, after celecoxib treatment either with or without
radiation, to further determine the mechanisms underlying COX-2-
dependent radiosensitization as the result of treatment with COX-2
selective inhibitors. Radiation treatment alone was shown to induce
significant G2-M arrest, which is a well-known phenomenon
(reviewed in ref. 39). However, this radiation-induced G2-M arrest
was enhanced and sustained to a greater degree in the COX-2-
overexpressing cells than in their COX-2 low-expressing counter-
parts. This implies that COX-2 expressionmay be associatedwith the
regulation of G2-M phase, such as the G2-M checkpoint, after
treatment with DNA-damaging agents, including radiation.
Celecoxib treatment alone was shown to induce G1 arrest in all
four of the tested cell lines, and this has been already shown in many
previous reports and was an expected result. However, celecoxib
treatment combined with radiation treatment was shown to induce
different types of cell cycle changes in the cells. Celecoxib treatment
was shown to attenuate radiation-induced G2-M arrest in the COX-2-
overexpressing HCT-116-COX-2 cells or resulted in only minor
changes in the duration of radiation-induced G2-M arrest in the
COX-2-overexpressing AN cells. By way of contrast, celecoxib
treatment further enhanced radiation-induced G2-M arrest in the
COX-2 low-expressing cells. Experiments with NS-398 yielded similar
results, although the attenuation of radiation-induced G2-M arrest
in the COX-2-overexpressing HCT-116-COX-2 cells, which was
observed as the result of celecoxib treatment in the same cells, was
not observed in conjunction with this drug. These results indicate
that COX-2 selective inhibitors initiate dual COX-2-dependent
actions on cell cycle regulation after radiation treatment. To explain
this unique phenomenon, we hypothesized that COX-2 overexpres-
sion in these cells both promotes and sustains the activation of G2-M
checkpoint after radiation, thereby enhancing radiation-induced
Figure 5. Cell cycle analyses after celecoxib F radiation treatment in the
AN and AS (A ) and HCT-116-mock and HCT-116-COX-2 (B) cells or after
NS-398 F radiation treatment in the HCT-116-mock and HCT-116-COX-2 cells
(C ). The attached cells were exposed to appropriate concentrations of celecoxib,
NS-398, or vehicle (DMSO) for 4 hours, irradiated (9 Gy for AN and AS or 6 Gy
for HCT-116-mock and COX-2), harvested, and fixed with 75% ethanol after an
additional 20, 44, or 68 hours of incubation in medium containing the relevant
drug. The cells were then stained with propidium iodide, and the number of cells
at different cell cycle phases was measured by flow cytometry. Bars, SE of three
independent experiments. *, P < 0.05. Radiation treatment alone manifested
higher and sustained rates of G2-M–phase cells in the COX-2-overexpressing
AN and HCT-116-COX-2 cells compared with what was observed in the COX-2
low-expressing AS and HCT-116-mock cells. Celecoxib or NS-398 effected
no changes (A and C ) or decreased (B ) the rates of G2-M–phase cells after
radiation treatment in AN or HCT-116-COX-2 cells, whereas these drugs were
shown to further increase the rates of G2-M–phase cells after radiation treatment
in the AS cells (A ) or HCT-116-mock cells (B and C ).
Table 2. Apoptosis induction by celecoxib in AN, AS,
HCT-116-mock, and HCT-116-COX-2 cells
Treatment group 24 h 48 h 72 h
AN cells
Control 0.47 F 0.14* 0.73 F 0.08 1.19 F 0.10
Celecoxib 50 Amol/L 0.44 F 0.15 0.51 F 0.01 3.47 F 0.05
Radiation 9 Gy 1.16 F 0.28 2.32 F 0.07 4.00 F 0.31
Radiation + celecoxib 1.10 F 0.21 1.80 F 0.39 3.88 F 0.80
AS cells
Control 0.80 F 0.08 1.34 F 0.16 2.12 F 0.11
Celecoxib 50 Amol/L 0.94 F 0.11 1.23 F 0.20 2.73 F 0.40
Radiation 9Gy 0.86 F 0.15 3.67 F 1.24 4.94 F 1.80
Radiation + celecoxib 1.29 F 0.22 2.14 F 0.02 3.55 F 0.11
HCT-116-mock cells
Control 1.77 F 0.43 1.82 F 0.59 1.11 F 0.04
Celecoxib 40 Amol/L 1.99 F 0.54 1.70 F 0.24 1.34 F 0.26
Radiation 6Gy 1.86 F 0.94 2.23 F 0.45 3.85 F 0.28
Radiation + celecoxib 2.18 F 0.78 2.33 F 0.51 2.78 F 0.16
HCT-116-COX-2 cells
Control 2.62 F 0.92 2.30 F 0.32 2.80 F 0.23
Celecoxib 40 Amol/L 3.67 F 1.13 4.43 F 0.30 4.22 F 1.02
Radiation 6Gy 4.43 F 0.54 6.54 F 0.98 12.85 F 3.11
Radiation + celecoxib 5.39 F 0.98 5.75 F 0.47 7.87 F 0.58
*Mean F SE from three independent experiments.
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G2-M arrest to protect the cells against radiation, and that COX-2
selective inhibitors inhibit this G2-M checkpoint promotion in COX-2-
overexpressing cells. The COX-2-overexpressing cells may then
induce higher and sustained degrees of G2-M arrest after radiation
compared with that in the COX-2 nonexpressing or low-expressing
cells, and COX-2 selective inhibitorsmay inhibit this prolonged G2-M
arrest in COX-2-overexpressing cells. In such a case, more radiation-
damaged cells will then enter mitosis without appropriate repair,
and die, than would if only radiation treatment had been applied.
The number of cells in the G2-M phase may decrease, then, as the
result of increased cell death, or may merely fail to increase, as flow
cytometric analysis after propidium iodide staining alone cannot
distinguish the cells in the G2 phase from those in mitotic phase.
This hypothesis may constitute a mechanism underlying the
radiation-enhancing effects of COX-2 selective inhibitors in COX-2-
overexpressing cells. In contrast, COX-2 selective inhibitors may also
exert a radiation-induced G2-M arrest enhancement effect in COX-2
nonexpressing or low-expressing cells by a yet unknownmechanism.
If this is the case, then the number of cells in the G2-Mphase could be
increased as the result of the combined treatment of these drugs
with radiation. The relationship between this radiation-induced
G2-M arrest enhancement effect and the lack of radiation-enhancing
effect observed when these drugs are administered to COX-2
nonexpressing or low-expressing cells remains a matter of some
controversy and requires further investigation, including separate
analyses of cells in G2 or mitotic phase. These cell cycle–regulating
effects may constitute a common feature of COX-2 selective
inhibitors, as studies of two distinct COX-2 selective inhibitors
(celecoxib and NS-398) yielded almost identical results. To the best of
our knowledge, the COX-2–dependent dual action of COX-2 selective
inhibitors on irradiated cells has not yet been reported. Further
studies are currently under way to define the optimum treatment
schedule of COX-2 selective inhibitors relative to radiation, to
maximally induce attenuation of radiation-induced G2-M arrestwith
these drugs, and to elucidate the molecular mechanisms underlying
these unique properties of COX-2 selective inhibitors as well as their
relationships with radiosensitization.
In summary, we conclude that the radiation-enhancing effects
associated with celecoxib, a COX-2 selective inhibitor, occur in a
COX-2 expression-dependent manner in the cells. These effects do
not seem to originate from attenuated prostaglandin generation by
celecoxib, nor do they seem to be the result of increased radiation-
induced apoptosis. Celecoxib (or NS-398) exhibited a dual mode of
action on cell cycle regulation after combined treatment with
radiation; no changes or attenuated radiation-induced G2-M arrest
were observed in the COX-2-overexpressing cells, and this effect
may allow the arrested cells to enter mitosis and die after radiation.
By way of contrast, celecoxib further enhanced radiation-induced
G2-M arrest in the COX-2 low-expressing cells. The molecular
mechanisms underlying these celecoxib-associated effects will
require further elucidation, and these results may bear some
clinical importance with regard to potential applications of
celecoxib in cancer patients undergoing radiotherapy.
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